Bremelanotide (PT-141 / Vyleesi) – Full Details & Benefits 

1. Basic Introduction

Bremelanotide (code name PT-141, brand name Vyleesi®) is a synthetic cyclic heptapeptide and a stabilized analog of α-MSH (alpha-melanocyte-stimulating hormone). It is a melanocortin receptor agonist developed to regulate sexual desire and arousal via central nervous system pathways.

• Classification: Peptide / Melanocortin receptor agonist
• Molecular formula: C₅₀H₆₈N₁₄O₁₀
• Appearance: White lyophilized powder (research grade) or sterile solution for injection
• Form: Subcutaneous injection (1.75 mg/0.3 mL auto-injector)
• Purity: ≥98% HPLC
• Key targets: MC1R, MC3R, MC4R (brain & skin)
• FDA approval: June 2019 (for premenopausal women with HSDD)

2. Mechanism of Action

Bremelanotide binds to and activates melanocortin receptors (MCRs) in the brain (hypothalamus, limbic system) and skin:

• MC4R (primary): Modulates sexual desire, arousal & motivation; boosts dopaminergic pathways linked to sexual reward.
• MC3R: Regulates energy balance, mood & sexual responsiveness.
• MC1R: Stimulates melanin production → mild skin darkening (tan).
• Central (not vascular) action: Unlike ED drugs (e.g., sildenafil), it works via brain desire centers, not blood flow.

3. Main Benefits & Effects

1. Treats Female Hypoactive Sexual Desire Disorder (HSDD)

• FDA-approved indication: Acquired, generalized HSDD in premenopausal women (low desire causing distress).
• Clinical results: In Phase 3 trials, it increased sexual desire, reduced sexual distress, and improved satisfying sexual events vs. placebo.
• On-demand use: Injected 45 minutes before activity; effects last ~8–12 hours.
• Non-hormonal: No estrogen/testosterone; safe for women avoiding hormone therapy.

2. Enhances Sexual Arousal & Satisfaction

• Boosts subjective arousal, sensitivity & orgasmic function in women with HSDD.
• Improves sexual motivation & responsiveness to stimuli.

3. Off-Label: Male Sexual Health (Research/Clinical Use)

• Erectile dysfunction (ED): Improves erection quality & duration (especially with PDE5 inhibitors).
• Low libido: Increases sexual desire & drive in men.

4. Mild Skin Tanning (MC1R effect)

• Stimulates natural melanin → gradual, even bronze skin tone.
• Reduces sunburn risk; no UV exposure needed.

5. Appetite & Metabolic Support (Research)

• Modulates MC4R → mild appetite suppression & reduced cravings.
• May support body recomposition (fat loss, muscle preservation) in preclinical models.

6. Mood & Stress Regulation

• Activates limbic MCRs → mood lift, reduced anxiety & emotional balance.

4. Dosage & Administration (Research/Clinical)

• Standard dose: 1.75 mg subcutaneous injection (abdomen/thigh) 45–60 minutes before sexual activity.
• Frequency: Max 1 dose every 24 hours; not daily long-term.
• Research form: Lyophilized powder reconstituted with bacteriostatic water (1–2 mg/mL).

5. Safety & Side Effects

Common Mild (Transient)

• Flushing (face/neck warmth)
• Mild nausea (10–15% users)
• Headache (mild, short-lived)
• Injection site redness/itching
• Mild blood pressure spike (+2–4 mmHg, transient)

Rare/Serious

• Severe hypertension (avoid in uncontrolled high BP)
• Allergic reaction (rare)
• Not for pregnant/nursing women

Key Safety Notes

• No addiction potential
• No hormonal disruption
• Not for postmenopausal women or men (FDA-approved label)

6. Summary

Bremelanotide (PT-141/Vyleesi) is a first-in-class melanocortin peptide that targets brain MC3R/MC4R to boost sexual desire & arousal—the only FDA-approved non-hormonal treatment for HSDD in premenopausal women. It also offers off-label benefits for male libido/ED, mild natural tanning, and appetite control. Its central mechanism (brain desire, not blood flow) makes it unique from other sexual health drugs.

Research Use Only. This catalog information is reproduced from the customer legacy website. Products are not for human or veterinary use. Confirm current specification, availability and documentation before ordering.